Royalty Pharma: “I can’t believe, sir, how low this stock is. … This company is doing so well. I really don’t know what to say. It is doing incredibly well. They ought to be able to raise the dividend, but they own stakes in a lot of different drugs. I would want to stay long this stock.”

Canadian Pacific: “It’s a buy. I think it’s the laggard in the group because of the transaction. I mean, obviously you’ve seen what we’re doing with Union Pacific in the [CNBC Investing Club.] It’s been such a monster. I think that that railroad will be playing catch up to UNP.”

Danaos: I’m not going to recommend containership stocks. … These are ones where I can look so great or so bad, and I’d rather just go with something consistent.”

You Might Like

Standard Lithium: “I think it can go higher because parts of the battery are really in obvious demand, but I am sticking with my new fave: MP Materials.”

Ionis Pharmaceuticals: “Doesn’t have enough juice for me. Never really started making a lot of money. I just can’t recommend them. I can’t. I like the ones we talked about [for the CNBC Investing Club] a lot more.”

Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.

Disclaimer